BVF 247Alternative Names: BVF-247
Latest Information Update: 08 Apr 2008
At a glance
- Originator Pharma Pass II LLC
- Developer Biovail Corporation
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 17 Mar 2008 Discontinued - Preclinical for Cardiovascular disorders in USA (unspecified route)
- 07 Nov 2007 Preclinical trials in Cardiovascular disorders in USA (unspecified route)